Clinical Trial Update: IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating IL13-PE38QQR infusion after surgical resection, followed by radiation therapy with or without temozolomide, in patients with newly diag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• Oligoastrocytoma

Drugs mentioned

• IL13-PE38QQR
• Temozolomide (Temozolomide)

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Status: COMPLETED